k8¿­·¢(Öйú)

ÕâÊÇÃèÊöÐÅÏ¢

ÐÂÎÅ×ÊѶ

ÐÂÎÅ×ÊѶ
ÁôÑÔ×Éѯ
Óë×îÐÂÏûÏ¢±£´æͬ²½
/
/
ÈçºÎÀûÓõ°°×ÖÊ×éѧ¼¼ÊõÇÉÃîµØ½øÐдó¶ÓÁÐÑо¿£¿

ÈçºÎÀûÓõ°°×ÖÊ×éѧ¼¼ÊõÇÉÃîµØ½øÐдó¶ÓÁÐÑо¿£¿

  • ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
  • ×÷ÕߣºÈðÈð
  • À´Ô´£ºk8¿­·¢(Öйú)¹«ÖÚºÅ

¡¾¸ÅÒªÃèÊö¡¿µ°°×ÖÊ×éѧÒѾ­ÔÚÁÙ´²±êÖ¾ÎïÑо¿ÖÐÓÐÁ˹㷺ºÍÉî¶ÈµÄÓ¦Óᣲ»½öÈç´Ë£¬µ°°×ÖÊ×éѧ»¹¿ÉÒÔ½Òʾ¼²²¡µÄ·¢Éú»úÖÆ£¬·¢ÏÖDZÔÚµÄÒ©Îï°Ðµã£¬Ö¸µ¼ÁÙ´²ÓÃÒ©¡£

ÈçºÎÀûÓõ°°×ÖÊ×éѧ¼¼ÊõÇÉÃîµØ½øÐдó¶ÓÁÐÑо¿£¿

¡¾¸ÅÒªÃèÊö¡¿µ°°×ÖÊ×éѧÒѾ­ÔÚÁÙ´²±êÖ¾ÎïÑо¿ÖÐÓÐÁ˹㷺ºÍÉî¶ÈµÄÓ¦Óᣲ»½öÈç´Ë£¬µ°°×ÖÊ×éѧ»¹¿ÉÒÔ½Òʾ¼²²¡µÄ·¢Éú»úÖÆ£¬·¢ÏÖDZÔÚµÄÒ©Îï°Ðµã£¬Ö¸µ¼ÁÙ´²ÓÃÒ©¡£

  • ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
  • ×÷ÕߣºÈðÈð
  • À´Ô´£ºk8¿­·¢(Öйú)¹«ÖÚºÅ
  • ·¢²¼Ê±¼ä£º2021-11-23 13:39
  • ·ÃÎÊÁ¿£º
ÏêÇé

µ°°×ÖÊ×éѧÒѾ­ÔÚÁÙ´²±êÖ¾ÎïÑо¿ÖÐÓÐÁ˹㷺ºÍÉî¶ÈµÄÓ¦Óᣲ»½öÈç´Ë£¬µ°°×ÖÊ×éѧ»¹¿ÉÒÔ½Òʾ¼²²¡µÄ·¢Éú»úÖÆ£¬·¢ÏÖDZÔÚµÄÒ©Îï°Ðµã£¬Ö¸µ¼ÁÙ´²ÓÃÒ©¡£´Ë´ÎΪ¶ÁÕß·ÖÏíһƪ¹ú¼Ê¶àÖÐÐÄ£¬´ó¶ÓÁеļ²²¡Õï¶Ï¡¢Ô¤ºóºÍҩЧ±êÖ¾ÎïµÄÑо¿¡£Ñо¿Õßͨ¹ý̵Һµ°°×ÖÊ×éѧ·¢ÏÖÁ˺ÍÖ§Æø¹ÜÀ©ÕÅÑÏÖس̶ÈÏà¹ØµÄ±êÖ¾Î²¢ÔÚ¶à¸ö¶ÀÁ¢¶ÓÁÐÖнøÐÐÁËÑéÖ¤¡£Ïà¹Ø³É¹ûÔÚ½ñÄê·¢±íÓÚLancet Respir Med£¨IF:30.7£©¡£±¾Ñо¿½«ÈçºÎÇÉÃîµØ½øÐпÆѧµÄ¡¢ºÏÀíµÄºÍ´´ÐÂÐԵĶÓÁÐÑо¿¹æ»®¡¢×î´ó³Ì¶ÈµØºÏÀíÀûÓÃÁÙ´²×ÊÔ´µÈ´ó¼Ò¹Ø×¢µÄ¿ÆÑÐÇÏÃÅ£¬ÌåÏÖµÄÁÜÀ쾡Ö£¬ÖµµÃ´ó¼Ò²Î¿¼¡£

 

|   µ°°×ÖÊ×éѧ·¢ÏÖÓëÖ§Æø¹ÜÀ©ÕÅÑÏÖس̶ÈÏà¹ØµÄDZÔÚ±êÖ¾Îï

Ñо¿ÕßÊ×ÏÈÍƲâÖضȺÍÇá¶ÈµÄÖ§Æø¹ÜÀ©ÕÅ»¼Õß´æÔÚ²»Í¬µÄÑ×֢״̬¡£Òò´ËÑо¿ÕßÄÉÈëÁË20ÀýÖØÖ¢ºÍ20ÀýÇáÖ¢µÄ»¼Õߣ¬²É¼¯ÌµÒº£¬¿ªÕ¹ÁËlabel freeµ°°×ÖÊ×éѧÑо¿£¨Í¼1A£©¡£ÔÚËùÓÐÑù±¾ÖÐ×ܹ²¼ø¶¨ÁË709¸öµ°°×£¨unique peptides > 2£©£¬ÆäÖмø¶¨ÁË96¸ö²îÒìµ°°×¡£ÕâЩ²îÒìµ°°×ºÜ¶àÓëÖÐÐÔÁ£Ï¸°ûÑ×Ö¢Ïà¹Ø£¬ÆäÖÐÖØÖ¢×éÖÐ×îÏÔÖøÉϵ÷µÄ¼¸¸öµ°°×ÓëÖÐÐÔÁ£Ï¸°ûÍâÓÕ²¶Íø£¨neutrophil extracellular trap, NET)ÓÐÖØÒª¹Øϵ£¬ÀýÈçRETN, S100-A9£¬S100-A8, neutrophil elastase ELANE , AZU1, MPO£¬LCN2£¨Í¼1B£©¡£Ñо¿ÕßÀûÓÃELISA¶ÔÆäÖÐ3¸öµ°°×ELANE¡¢RETNºÍS100A12µÄ½øÐÐÁËÑéÖ¤£¬¼ì²â½á¹ûÓëÖÊÆ×Ò»Ö£¨Í¼1C£©¡£

 

ͼ1 ̵Һµ°°×ÖÊ×éѧ·¢ÏÖDZÔÚ±êÖ¾Îï

 

|   NETŨ¶È×÷Ϊ֧Æø¹ÜÀ©ÕŵÄÕï¶ÏºÍÔ¤ºó±êÖ¾Îï

Ç°ÆÚµÄ̵Һµ°°×ÖÊ×éѧ·¢ÏÖÁ˺ܶàNETµÄ³É·Öµ°°×ÔÚÖØÖ¢×éÖÐÏÔÖøÉϵ÷£¬¶øNETµÄÐγÉȷʵÓë·Î²¿Ñ×Ö¢ÃÜÇÐÏà¹Ø£¬Õâ¾Í˵Ã÷¼ì²âNETµÄŨ¶È¿ÉÄÜ¿ÉÒÔÕï¶ÏÖ§Æø¹ÜÀ©Õż²²¡µÄÑÏÖس̶È¡£Ñо¿Õß²ÉÓÃÁËELISA¼¼Êõ£¬¶Ô̵ҺµÄhistone-elastase ¸´ºÏÎïµÄŨ¶È½øÐмì²â£¬´Ó¶ø¶ÔNET½øÐж¨Á¿·ÖÎö¡£Ñо¿ÕßÔÚÁ½¸ö¶ÓÁÐÖпªÕ¹ÁËNETŨ¶ÈµÄ¼ì²â¡£Ê×ÏÈÊÇÒ»¸öµ¥ÖÐÐĵĶÓÁаüÀ¨151ÀýÖ§Æø¹ÜÀ©ÕÅ¡¢9ÀýÄÒÐÔÏËά¡¢66ÀýÂýÐÔ×èÈûÐԷβ¡¡¢10ÀýÏø´­ºÍ13Àý½¡¿µÕß¡£½á¹û·¢ÏÖÁËÖ§Æø¹ÜÀ©ÕÅ×éºÍÄÒÐÔÏËά×éµÄ̵ҺNETŨ¶ÈÏàËÆ£¬µ«ÊÇÏÔÖø¸ßÓÚÆäËûµÄ×é±ð£¨Í¼2A£©£»ÖØÖ¢Ö§Æø¹ÜÀ©ÕÅ×éÏÔÖø¸ßÓÚÇá¡¢ÖÐÖ¢×飨ͼ2B£©£»¸ßNETŨ¶ÈµÄ»¼Õß²¡Çé¶ñ»¯µÄ³Ì¶ÈÔö¼Ó£¨Í¼2C£©²¢ÇÒ×ÜÉú´æÂʽµµÍ£¨Í¼2D£©¡£Ñо¿ÕßÓÖͨ¹ýÁíÍâÒ»¸ö275ÀýÖ§Æø¹ÜÀ©ÕÅ»¼ÕߵĶàÖÐÐĶÓÁнøÐÐÁËÑéÖ¤£¬¼ì²â½á¹ûºÍÉÏÊöÒ»Ö¡£

 

ͼ2 NETŨ¶È×÷Ϊ֧Æø¹ÜÀ©ÕŵÄÕï¶ÏºÍÔ¤ºó±êÖ¾Îï

 

ϸ¾ú»áÓÕµ¼NETÐγÉ£¬²»Í¬NETµÄŨ¶È»òÐíºÍÌåÄÚ²»Í¬µÄϸ¾úÓйØ¡£Òò´ËÑо¿Õ߶ÔÉÏÊöµÚÒ»¸ö¶ÓÁеÄ151Àý»¼Õß½øÐÐÁË̵Һ16s rRNA²âÐò£¬·¢ÏÖÁ˸»º¬¼Ùµ¥°û¾ú»òÊÈѪ¸Ë¾úµÄ»¼ÕßÓÐןü¸ßµÄNETŨ¶È£¨Í¼3A£©¡£Ñо¿Õß»¹¶ÔÉÏÊöµÚ2¸ö¶ÓÁеÄ275Àý»¼Õß½øÐÐÁË̵Һ»òѪÇåµÄϸ°ûÒò×Ó¼ì²â£¬·¢ÏÖÁËNETŨ¶ÈºÍIL-10, TNF-α, IL-1βºÍIL-8ÏÔÖøÏà¹Ø£¨Í¼3B£©¡£ÕâЩ·ÖÎö½á¹û»òÐíΪºóÐøµÄ¼²²¡»úÖÆÑо¿ÌṩÁËÒ»¶¨µÄÏßË÷¡£

 

ͼ3 ·¢ÏÖºÍNETÏà¹ØµÄ΢ÉúÎïºÍϸ°ûÒò×Ó

 

|   NETŨ¶È×÷Ϊ֧Æø¹ÜÀ©ÕÅÓÃÒ©µÄ±êÖ¾Îï

΢ÉúÎï×éѧ·¢ÏÖÁËijЩ²¡Ô­¾úÔÚNETŨ¶È¸ßµÄµÄÖØÖ¢»¼ÕßÖÐÊýÁ¿Ôö¼Ó£¬Òò´ËÑо¿ÕßÍƲâÀûÓÿ¹ÉúËØ´¦Àí»á¼õÉÙNETµÄŨ¶È¡£Ñо¿ÕßÊ×ÏÈÄÉÈëÁË20Àý¶ñÐÔµÄÖ§Æø¹ÜÀ©ÕÅ»¼Õߣ¬·Ö±ðÔÚ»ùÏßÆںͿ¹ÉúËØ´¦Àí14ÌìºóÊÕ¼¯ÌµÒº½øÐÐlabel freeµ°°×ÖÊ×éѧ¡£½á¹û·¢ÏÖÁË¿¹ÉúËØ´¦Àíºó39¸öµ°°×·¢ÉúÁ˱仯£¬°üÀ¨23¸öϵ÷ºÍ16¸öÉϵ÷µÄµ°°×£¨Í¼4A£©£¬ÆäÖÐ10¸öϵ÷µÄµ°°×ºÍNETµÄÐγÉÓйأ¨Í¼4B£©£¬ËµÃ÷¿¹ÉúËØ´¦Àí»òÐí¿ÉÒÔ¼õÉÙNETµÄŨ¶È¡£µ«ÊÇÑо¿Õß·¢ÏÖÁËÆäÖÐÂÌŧ¼Ùµ¥°û¾úÑôÐԵĻ¼ÕßÔÚ»ùÏßÆÚNETµ°°×µÄ·á¶È¸ü¸ß£¬²¢ÇÒÔÚÕâÀàÈËȺÖп¹ÉúËØ´¦ÀíºóijЩNETµ°°×¼õÉٵķù¶È±äС£¬ÀýÈçMPO¡¢ELANEºÍAZU1£¨Í¼4C£©¡£ÎªÁËÑéÖ¤Õâ¸ö½á¹û£¬Ñо¿ÕßÄÉÈëÁË11ÀýÂÌŧ¼Ùµ¥°û¾úÑôÐԵĻ¼Õߣ¬9ÀýÒõÐÔ»¼Õߣ¬ÀûÓÿ¹ÉúËØ´¦Àí14Ììºó£¬¶Ô±È̵ҺÖÐNETŨ¶ÈµÄ±ä»¯¡£½á¹û·¢ÏÖÁ˾ø´ó¶àÊýÒõÐÔ»¼Õß¿¹ÉúËØÖÎÁƺó̵ҺNETŨ¶ÈÏÔÖø½µµÍ£¬µ«ÊǾø´ó¶àÊýÑôÐÔ»¼ÕßûÓÐÏÔÖø±ä»¯£¨Í¼4D£©¡£²¢ÇÒÕâЩÂÌŧ¼Ùµ¥°û¾úÑôÐÔ»¼Õß²¡Çé¶ñ»¯¼Ó¾çµÄʱ¼ä»áÏÔÖøËõ¶Ì¡£ÕâЩ½á¹û°µÊ¾ÁË̵ҺNETŨ¶ÈÔÚ¿¹ÉúËØ´¦Àíºó±ä»¯²»Ã÷ÏÔºÍÂÌŧ¼Ùµ¥°û¾úÑôÐԵĻ¼Õ߶Կ¹ÉúËØ´¦Àí²»Ãô¸ÐÏà¹Ø¡£

 

ͼ4 ¿¹ÉúËØ´¦Àí¸Ä±äNETŨ¶È

 

´ó»·ÄÚõ¥ÀàÒ©Îï¶ÔÖÎÁÆÖ§Æø¹ÜÀ©ÕÅÊǷdz£ÓÐЧµÄÒ©ÎÌرðÊǶÔÂÌŧ¼Ùµ¥°û¾úÑôÐԵĻ¼Õß¡£µ«ÊÇ´ó»·ÄÚõ¥ÀàÒ©Îï²»¾ßÓп¹ÂÌŧ¼Ùµ¥°û¾úµÄ×÷Óã¬ËùÒÔÖÎÁÆÓÐЧÐÔÊÜÒæÓÚÄÄЩ·½Ãæ²¢²»Çå³þ¡£ÉÏÊöµÄµ°°×ÖÊ×éѧ·¢ÏÖÁËÂÌŧ¼Ùµ¥°û¾úÑôÐԵĻ¼ÕßµÄNETŨ¶ÈÏà¶Ô¸ü¸ß£¬ËùÒÔÑо¿ÕßÍƲâ´ó»·ÄÚõ¥ÀàÒ©Îï»òÐíͨ¹ý¼õÉÙNETŨ¶È·¢»ÓÁÆЧ¡£Ñо¿ÕßÊ×ÏÈÄÉÈëÁË52¸öÂÌŧ¼Ùµ¥°û¾úÑôÐÔµÄÖ§Æø¹ÜÀ©ÕÅ»¼Õߣ¬ÆäÖÐ26Àý»¼ÕßÿÖÜ3´Î·þÓÃÿ´Î¼ÁÁ¿250mgµÄ°¢ÆæùËØ£¬³ÖÐø1Ä꣬ÁíÍâ26Àý²»½ÓÊÜ°¢ÆæùËØÖÎÁÆ£¬½á¹ûºÍ»ùÏßÆÚÏà±È£¬Ò©ÎïÖÎÁƺóµÄ̵ҺNETŨ¶ÈÏÔÖø½µµÍ£¬µ«ÊÇ·ÇÖÎÁÆ×éȴûÓб仯£¨Í¼5A£©¡£´ËÀàÒ©Îï´¦ÀíNETÏà¹ØµÄÆäËû¼²²¡ÊÇ·ñÒ²ÓÐÏàËƵÄЧ¹ûÄØ¡£ÓÚÊÇÑо¿ÕßÓÖÄÉÈëÁËÈË47ÀýÏø´­»¼Õߣ¬ÆäÖÐ27Àý°¢ÆæùËØÖÎÁÆ£¬20ÀýÊ©¼Ó°²Î¿¼Á£¬½á¹ûͬÑù·¢ÏÖÁËÏà±È°²Î¿¼Á×飬ҩÎïÖÎÁÆ×éµÄ̵ҺNETŨ¶ÈÏÔÖø½µµÍ£¨Í¼5B£©¡£

 

ͼ5 ´ó»·ÄÚõ¥ÀàÒ©Îï¸Ä±äNETŨ¶È

 

ͨ¹ýÒÔÉϽâ¶ÁÎÒÃÇ¿ÉÒÔ¿´µ½µ°°×ÖÊ×éѧ·¢ÏÖÁ˹ؼü²îÒìµ°°×ÊÇÕû¸öÑо¿µÄµÚÒ»¹Ø£¬Ò²ÊÇ×î¹Ø¼üµÄÒ»²½£¬Ö®ºóÔÙ»ùÓÚµ°°×ÖÊ×éѧµÄ·ÖÎö¿ªÕ¹±êÖ¾ÎïµÄÑéÖ¤·ÖÎö¡£ÌرðÖµµÃÒ»ÌáµÄÊDZ¾Ñо¿Í¨¹ýµ°°×ÖÊ×éѧ»¹·¢ÏÖÁË×÷ÓûúÀí²»Ã÷µÄÓÐÁÙ´²Ð§¹ûÒ©ÎïµÄDZÔÚ»úÖÆ£¬¿ÉÄÜΪÁÙ´²Ö¸µ¼ÓÃÒ©ÌṩеÄ;¾¶¡£

 

»ªÓ¯ÊӽǶÁÕßÃÇÒ²Ïë½øÐÐÀàËÆÑо¿£¬¿É²Î¿¼ÒÔÏÂÑо¿Ë¼Â·£º

 

 

k8¿­·¢(Öйú)ÔÚµ°°××éѧÁìÓò£¬ÌرðÊÇÖÊÆ×¼ì²âºÍÊý¾Ý·ÖÎöµÈ·½Ã涼ÓÐÇ¿´óµÄרҵÍŶÓ£¬²¢ÇÒ¾ßÓжà¸ö´ó¶ÓÁбêÖ¾ÎïÑо¿µÄÏîÄ¿¾­Ñé¡£ÔÚÇ°ÆÚɸѡ±êÖ¾Îï½×¶Î£¬k8¿­·¢(Öйú)¿ÉÒÔÌṩ¶àÖÖ·Ç°ÐÏòµ°°××éѧ¼¼Êõ°üÀ¨label free¡¢TMT¡¢DIAºÍ4Dµ°°×ÖÊÆ×¼¼Êõ£¬ºóÆÚ±êÖ¾ÎïÑéÖ¤½×¶ÎÌṩMRM¡¢PRM°ÐÏòµ°°××éѧ¼¼Êõ£¬½ßÁ¦Îª¹ã´óÁÙ´²¿ÆÑÐÈËÔ±Ìṩ¸üºÃµÄ±êÖ¾ÎïÑо¿²ßÂԺͷ½°¸¡£

|   Ïà¹ØÎÄÏ×

1.  Keir HR, Shoemark A, Dicker AJ, Perea L, Pollock J, Giam YH et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. [J]. Lancet Respir Med. 2021;9(8):873-884.

 

k8¿­·¢(Öйú)

µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã

µç»°£º400-869-2936£¬021-33968791

ÓÊÏ䣺support@wayenbiotech.com

´«Õ棺021-33938792

QQ£º2120485725

Õ½ÂÔºÏ×÷

Õ½ÂÔºÏ×÷

·¢²¼Ê±¼ä£º2021-08-11 17:21:10

|    Full Moon    |    RayBiotech    |    CDI    |    IZON    |    Bio-Rad    |    R&D Systems    |    IsoPlexis    |    ÄÏÄ£ÉúÎï    |    Å·Ò×ÉúÎï    |    ÆäÃ÷ÐÅÏ¢    |    ÃÀ¼ªÉúÎï    |    ÂóÌØ»æÆ×    | 

 

Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿­·¢(Öйú)Ô­´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿­·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£

רÀû´úÂë

·¢²¼Ê±¼ä£º2023-06-09 17:38:30
Copyright @ 2021 ÉϺ£k8¿­·¢(Öйú)Ò½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾ °æȨËùÓÐ
Record »¦ICP±¸2022031428ºÅ-1
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ÉϺ£
ËÑË÷
ËÑË÷
¹Ø±Õ
¿Í»§ÁôÑÔ
ÑéÖ¤Âë